139 related articles for article (PubMed ID: 37320996)
1. Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Best Pract Res Clin Obstet Gynaecol; 2023 Jul; 89():102350. PubMed ID: 37320996
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
4. Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation.
Koloda Y; Korsak V; Rozenson O; Anshina M; Sagamonova K; Baranov I; Yakovenko S; D'Hooghe T; Ershova A; Lispi M
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):134-148. PubMed ID: 35216907
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.
Lehert P; Kolibianakis EM; Venetis CA; Schertz J; Saunders H; Arriagada P; Copt S; Tarlatzis B
Reprod Biol Endocrinol; 2014 Feb; 12():17. PubMed ID: 24555766
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.
Conforti A; Esteves SC; Humaidan P; Longobardi S; D'Hooghe T; Orvieto R; Vaiarelli A; Cimadomo D; Rienzi L; Ubaldi FM; Zullo F; Alviggi C
Reprod Biol Endocrinol; 2021 Jun; 19(1):91. PubMed ID: 34154604
[TBL] [Abstract][Full Text] [Related]
7. A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chen MJ; Yi YC; Guu HF; Chen YF; Kung HF; Chang JC; Chuan ST; Chen LY
Front Endocrinol (Lausanne); 2022; 13():931756. PubMed ID: 36046790
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.
Bühler KF; Fischer R; Verpillat P; Allignol A; Guedes S; Boutmy E; Bilger W; Richter E; D'Hooghe T
Reprod Biol Endocrinol; 2021 Jun; 19(1):90. PubMed ID: 34134695
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment.
Humaidan P; Schertz J; Fischer R
BMJ Open; 2015 Jul; 5(7):e008297. PubMed ID: 26141305
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment.
Marrs R; Meldrum D; Muasher S; Schoolcraft W; Werlin L; Kelly E
Reprod Biomed Online; 2004 Feb; 8(2):175-82. PubMed ID: 14989794
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
[TBL] [Abstract][Full Text] [Related]
12. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chang JC; Yi YC; Chen YF; Guu HF; Kung HF; Chen LY; Chuan ST; Chang YM; Chen MJ
Arch Gynecol Obstet; 2024 Feb; 309(2):699-706. PubMed ID: 38099955
[TBL] [Abstract][Full Text] [Related]
13. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.
Bühler K; Roeder C; Schwarze JE; Lispi M; Allignol A; Falla E; Lukyanov V; D Hooghe T; Fischer R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):188-202. PubMed ID: 35304097
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles of cumulus cells obtained from women treated with recombinant human luteinizing hormone + recombinant human follicle-stimulating hormone or highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone alone.
Gatta V; Tatone C; Ciriminna R; Vento M; Franchi S; d'Aurora M; Sperduti S; Cela V; Borzì P; Palermo R; Stuppia L; Artini PG
Fertil Steril; 2013 Jun; 99(7):2000-8.e1. PubMed ID: 23472943
[TBL] [Abstract][Full Text] [Related]
17. A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study.
Choi BC; Zhou C; Ye H; Sun Y; Zhong Y; Gong F; Sini I; Abramova N; Longobardi S; Hickey M; D'Hooghe T
Reprod Biol Endocrinol; 2022 Jan; 20(1):15. PubMed ID: 35039049
[TBL] [Abstract][Full Text] [Related]
18. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study.
Matorras R; Prieto B; Exposito A; Mendoza R; Crisol L; Herranz P; Burgués S
Reprod Biomed Online; 2009 Dec; 19(6):879-87. PubMed ID: 20031032
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study.
Bühler KF; Fischer R
Gynecol Endocrinol; 2012 May; 28(5):345-50. PubMed ID: 22115012
[TBL] [Abstract][Full Text] [Related]
20. Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.
Orvieto R; Venetis CA; Fatemi HM; D'Hooghe T; Fischer R; Koloda Y; Horton M; Grynberg M; Longobardi S; Esteves SC; Sunkara SK; Li Y; Alviggi C
Front Endocrinol (Lausanne); 2021; 12():675670. PubMed ID: 34040586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
